摘要
肝细胞癌(HCC)是一种常见的恶性肿瘤,其发病机制尚不明确,但发病率高。大多数患者在癌症晚期时确诊,因此治疗手段和治疗药物的选择有限,整体预后较差。HCC的发病可能涉及遗传学和表观遗传学改变,在HCC中Wnt、磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)/哺乳动物雷帕霉素靶蛋白(mTOR)、Janus激酶/信号转导及转录活化因子(JAK/STAT)等信号通路异常激活,并参与了肿瘤细胞的增殖、侵袭、迁移、耐药等。部分肝脏差异性表达的长链非编码RNA(lncRNA)参与HCC中Wnt、PI3K/Akt/mTOR、JAK/STAT信号通路的表达调控且涉及多种机制,深入研究lncRNA与相关信号通路的作用对于HCC治疗及预测有重要作用。
Hepatocellular carcinoma(HCC)is a common malignant tumor with unclear pathogenesis and high incidence.Most patients are at advanced stage of cancer when diagnosed,facing limited choice of treatment methods and drugs,and overall poor prognosis.The pathogenesis of HCC may involve genetic and epigenetic changes.In HCC,Wnt,phosphoinositide 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin(mTOR),Janus kinase(JAK)/signal transducer and activator of transcription(STAT)and other signaling pathways are abnormally activated,which are involved in the proliferation,invasion,migration and drug resistance of HCC.Some differentially expressed long non-coding RNA(lncRNA)in liver mediate the expression regulation of Wnt,PI3K/Akt/mTOR and JAK/STAT,which involve multiple mechanisms.In-depth study of the role of lncRNA and related signaling pathways is important for the treatment and prediction of HCC.
作者
孔茵芝
谢杨益
林洪升
李明芬
KONG Yinzhi;XIE Yangyi;LIN Hongsheng;LI Mingfen(Guangxi University of Chinese Medicine,Nanning 530200;Department of Laboratory,the First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530022,China)
出处
《医学综述》
CAS
2022年第16期3181-3187,共7页
Medical Recapitulate
基金
国家自然科学基金(81960840,82160829)。
